Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

40.75 +0.41 (+1.02%)
Streaming Delayed Price Updated: 9:34 AM EDT, Sep 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Xenon Reports Q2 2024 Financial Results and Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon to Report Q2 2024 Financial Results on August 8, 2024
Conference Call and webcast scheduled at 4:30 pm ET 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Earnings Outlook For Xenon Pharmaceuticals
Via Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
Via Benzinga
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
Via MarketBeat
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today
Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542... 
Via Benzinga
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.